AzTrials
AzTrials

Ovarian CancerPhase 3MAMOCNCT04227522

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

A Phase 3 study testing Rucaparib in people with Ovarian Cancer and Fallopian Tube Cancer, run by North Eastern German Society of Gynaecological Oncology at 17 sites in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

MAMOC is a multicenter, randomized, placebo controlled, double blind study including BRCA negative patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian… Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
Rucaparib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
42 participants
Where
17 sitesGermany
Study dates
8 Jun 2020to 1 Jul 2024
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Written informed consent and obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
  • Age ≥ 18.
  • Patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary in first line therapy.
  • Availability of archival tumor tissue for central next-generation sequencing (NGS) Analysis and no Detection BRCA mutation (BRCAnegative).
  • Treatment with Bevacizumab or respective biosimilar for 12 to 15 months, independent of dosage.
  • Patients who have completed first line platinum-taxane chemotherapy and at least stable disease after treatment with Bevacizumab before randomization.
Show all 21Show fewer
  • Patients must be randomized at least 3 weeks and no more than 9 weeks after their last dose of Bevacizumab (last dose is the day of the last infusion) and all major toxicities from the previous chemotherapy must have resolved to CTCAE grade 1 or better (except alopecia and peripheral neuropathy).
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Patients must have normal organ and bone marrow function:
  • Hemoglobin ≥ 10.0 g/dL independent of transfusion ≤ 14 days prior to Screening hemoglobin assessment
  • Absolute neutrophil count (ANC) ≥ 1.5 x 109 /L
  • Platelet count ≥ 100 x 109 /L
  • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); < 2 × ULN if hyperbilirubinemia is due to Gilbert's syndrome
  • Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤3 x ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN
  • Serum creatinine ≤ 1.5 x institutional ULN and creatinine clearance > 30 mL/min
  • Patients not receiving anticoagulant medication who have an International Normalized Ratio (INR) ≤1.5 and an Activated ProThrombin Time (aPTT) ≤1.5 x ULN.
  • Postmenopausal or evidence of non-childbearing status for women of childbearing potential prior to the first dose of study treatment. Female patients of childbearing potential must have a negative serum pregnancy test result ≤3 days prior to administration of the first dose of rucaparib.
  • Patients are considered to be of childbearing potential unless 1 of the following applies:
  • Considered to be permanently sterile. Permanent sterilization includes hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy; or
  • Is postmenopausal, defined as no menses for at least 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level consistently in the postmenopausal range (30 milli International Units/milliliter (mIU/mL) or higher) may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to confirm a postmenopausal state.
  • Female patients of reproductive potential must practice highly effective methods (failure rate < 1% per year) of contraception with their partners, if of reproductive potential, during treatment and for 6 months following the last dose of rucaparib or longer if requested by local authorities. Highly effective contraception includes: Ongoing use of progesterone only injectable or implantable contraceptives; Placement of an intrauterine device (IUD) or intrauterine system (IUS); Bilateral tubal occlusion; Sexual abstinence as defined as complete or true abstinence, acceptable only when it is the usual and preferred lifestyle of the patient; periodic abstinence (eg, calendar, symptothermal, post-ovulation methods) is not acceptable; or Sterilization of the male partner, with appropriate post-vasectomy documentation of absence of sperm in ejaculate.

Who cannot join

  • Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors) and Ovarian tumors of low malignant potential (e.g. borderline tumors), or low grade serous ovarian cancer, or low grade endometrioid ovarian cancer, or mucinous carcinoma.
  • Patients with myelodysplastic syndrome/acute myeloid leukemia history.
  • Patients receiving radiotherapy within 6 weeks prior to study treatment.
  • Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
  • Previous allogeneic bone marrow transplant.
  • Use of any other PARP-inhibitor in first line therapy.
Show all 25Show fewer
  • Administration of other simultaneous chemotherapy drugs, any other anti-cancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroidal antiemetics).
  • Clinically significant (e.g. active) cardiovascular disease.
  • Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or Sub-Arachnoids Hemorrhage (SAH) within 6 months prior to randomization.
  • History or evidence of hemorrhagic disorders within 6 months prior to randomization.
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of coagulation).
  • History or evidence for brain metastases or spinal cord compression.
  • History or evidence upon neurological examination of central nervous system (CNS) disease, unless adequately treated with standard medical therapy (e.g. uncontrolled seizures).
  • Significant traumatic injury during 4 weeks prior to randomization.
  • Non-healing wound, active ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require 3 weekly wound examinations.
  • Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease.
  • Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications.
  • Pregnant or lactating women, women of child-bearing potential who do not agree to the usage of highly effective contraception methods (see inclusion criteria).
  • Participation in another clinical study with an investigational product immediately prior to randomization.
  • Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  • Patients with a known hypersensitivity to Rucaparib or any of the recipients of the product.
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency Syndrome (AIDS)-related illness, or history of chronic hepatitis B or C.
  • Other active malignancy requiring treatment.
  • Patient who might be dependent on the sponsor, Clinical Research Organization (CRO), site or the investigator.
  • Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 Arzneimittelgesetz (AMG).

Trial locations and contacts

17 sites in 1 country.

17 sites in 1 country

Germany17 sites

  • Universitätsklinikum Aachen

    Aachen, 52074

  • ANregiomed Frauenklinik Ansbach

    Ansbach, 91522

  • Helios Klinikum Berlin-Buch

    Berlin, 13125

  • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum

    Berlin, 13353

  • Universitätsklinikum Bonn

    Bonn, 53127

  • Städtisches Klinikum Dessau

    Dessau, 06847

  • Universitätsklinikum Carl Gustav Carus

    Dresden, 01307

  • Kliniken Essen Mitte

    Essen, 45136

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, 20246

  • ViDia Christliche Kliniken Karlsruhe Vincentius-Diakonissen-Kliniken g AG

    Karlsruhe, 76135

  • Städtisches Krankenhaus Kiel

    Kiel, 24116

  • ZAGO-Zentrum für ambulante gynäkologische Onkologie

    Krefeld, 47805

  • Universitätsklinikum Mannheim

    Mannheim, 68167

  • LMU Klinikum Großhadern

    München, 81377

  • Universitätsklinikum Münster

    Münster, 48149

  • CaritasKlinikum Saarbrücken

    Saarbrücken, 66113

  • Helios Dr. Horst Schmidt Kliniken Wiesbaden

    Wiesbaden, 65199

Other trials in Germany

About this study

MAMOC is a multicenter, randomized, placebo controlled, double blind study including BRCA negative patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary in first line therapy.

Read the detailed description

The main scope of this trial is to determine progression free survival in BRCA negative patients treated with Rucaparib as maintenance therapy vs. Placebo after receiving Bevacizumab for 12 to 15 months.

BRCA negative patients will be stratified according to time point of surgery (adjuvant vs. neoadjuvant), result of surgery (tumor free vs. not tumor free resection), study site and response (complete response (CR) vs. partial response (PR)/SD) and randomized 2:1 to receive either Rucaparib (Arm A) or Placebo (Arm B).

In both of the arms, tumor assessments (CT or MRI) are performed before randomization, and every 6 months thereafter.

During treatment, clinical visits (blood cell counts, detection of toxicity) occur every 4 weeks. Physical examinations will take place every 12 weeks. Safety will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs).

About 30 sites in Germany will participate in this study to recruit 190 BRCA negative patientsin 24 months.

Being tested
Rucaparib, Placebos
Keywords
Rucaparib, maintenance therapy, Bevacizumab, Ovarian Cancer, BRCA negative
Medical subject headings
Ovarian Neoplasms, Fallopian Tube Neoplasms, Adenocarcinoma, Clear Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RucaparibDrug

    A starting dose of 600 mg Rucaparib is taken twice daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.

  • PlacebosDrug

    Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.

Study groups in NCT04227522
Study groupRoleWhat they receive
Arm A (Rucaparib)ExperimentalRucaparib treatment (starting dose 600 mg, twice daily) after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
Receives: Drug: Rucaparib
Arm B (Placebo)Placebo comparatorPlacebo treatment after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
Receives: Drug: Placebos

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression free survival (PFS)

    time from randomization until disease progression or death

    Measured: 48 months

Secondary outcomes (11)

  1. Progression free survival 2 (PFS2)

    time from randomization to second progression or death

    Measured: 48 months

  2. Quality of Life (QoL) 1

    Patients are asked to answer the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30). Responses of questions 1-28 are based on a 4-point scale (1=not at all; 4=Very much), with a higher score indicating a high degree of symptomatology and must therefore be assessed negatively. Responses of questions 29 and 30 are based on a 7-point scale (1=Very poor; 7=Excellent), with a higher score indicating a better global health status.

    Measured: 48 months

  3. Quality of Life 2

    Patients are asked to answer the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28). Responses are based on a 4-point scale (1=Not at all; 4=Very much), with a lower score indicating better symptoms.

    Measured: 48 months

  4. Quality of Life/ Global health status 3

    Patients are asked to answer the short version of the SF-36 Health Survey (SF-12). The questionnaire contains a total of 12 questions with different response options. For questions 1, 8 and 12 there are 5 (1=excellent, 5=bad), for question 2-3 there are 3 (1=yes, very restricted, 3=no, not restricted at all) and for questions 9-11 there are 6 response options (1= always, 6 = never). Questions 4-7 can be answered with "Yes" or "No".

    Measured: 48 months

  5. Quality of Life 4

    Patients are asked to answer the questionnaire Fatigue Symptom Inventory (FSI). Responses are based on a 10 point grading scale (0=not at all tired/ exhausted; 10=completely tired/ exhausted), with a lower score indicating a lower symptomatology of fatigue.

    Measured: 48 months

  6. Quality of Life 5

    Patients are asked to answer the Everyday Memory Questionnaire. Responses are based on a 5-point scale (1=occasionally; 5=very often), with a lower score indicating a better performance on memory associated Everyday activities.

    Measured: 48 months

  7. Quality of Life 6

    Patients are asked to answer a custom form of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events developed by the National Cancer Institute (NCI PRO-CTCAE™) Version 1.0. The frequency and strength of symptoms is queried. There are 5 possible answers: "not at all", "a little", "moderate", "quite", "very".

    Measured: 48 months

  8. Determination of time to next medical intervention

    (e.g. bowel obstruction, Ascites puncture)

    Measured: 48 months

  9. Time to next subsequent therapy

    e.g. chemotherapy

    Measured: 48 months

  10. Number of participants with treatment-related adverse events and/or serious adverse events as assessed by CTCAE v4.03

    AEs/SAEs

    Measured: 48 months

  11. Overall survival (OS)

    defined as time from Randomization to death by any cause

    Measured: 72 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jan 2020
  2. Study start8 Jun 2020
  3. Primary completion1 Dec 2023
  4. Study completion1 Jul 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
42 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04227522
Sponsor's protocol ID
NOGGO ov42
Acronym
MAMOC
Status last verified
Nov 2024
First submitted
20 Dec 2019
Last updated
15 Nov 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Scienctists may submit a request for scientific use of the data after the first publication. This request shall be examined by the working group. After signing an agreement, the anonymous data can be made available to the scientist (password protected).

Publications

  • Malhan D, Hesse J, Nelson N, Stankov K, Nguyen J, Aboumanify O, Garmshausen J, Rogmans G, Czogalla B, Gerber J, Koch M, Kupec T, Tome O, Witteler R, Deryal M, Eichbaum M, Sehouli J, Braicu EI, Relogio A. Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects. EBioMedicine. 2025 Jul;117:105764. doi: 10.1016/j.ebiom.2025.105764. Epub 2025 May 16.

    PubMed 40382284

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Rucaparib in people with Ovarian Cancer and Fallopian Tube Cancer, run by North Eastern German Society of Gynaecological Oncology at 17 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 21 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 17 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression free survival (PFS) (time frame: 48 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04227522, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in